April 25, 2018 | Bently Reserve, San Francisco
April 25, 2018 | Bently Reserve, San Francisco
Summit Speakers, Presenters, and Moderators
Vasudev Bailey, PhD
Partner, ARTIS Ventures
Award Presenter, Moderator
Dr. Vasudev Bailey is a partner at ARTIS Ventures. He was previously at Quid and McKinsey & Co. He was also the co-founder of GLG Insittute and Zufog. He received his PhD in biomedical engineering from the Johns Hopkins School of Medicine, where he was recognized as both a Siebel and a Medtronic Scholar. Dr. Bailey graduated magna cum laude and Phi Beta Kappa from University of California Irvine, where he was also recognized as both a Regents and a Henry Samueli Scholar. He has been an AWIS member since 2016.
Janet Bandows Koster, MBA
Executive Director and CEO, Association for Women in Science
Janet Bandows Koster is Executive Director and CEO of the Association for Women in Science (AWIS). Her newest book “Equitable Solutions for Retaining a Robust STEM Workforce,” addresses systemic factors leading to the dearth of women in STEM careers and its impact on the workforce. A sought-after speaker, she has presented at various conferences around the world including the International Gender Summit, the U.S. News STEM Solutions Conference, and the UNESCO Women in STEM meeting at the United Nations. Ms. Bandows Koster has authored numerous reports related to issues at the nexus of gender and STEM. Her work has appeared in the Chronicle of Higher Education, Inside Higher Ed, Forbes, the Journal of International Innovation, and Open Science EU. In 2016, she was named one of the 100 Inspiring Women in STEM by INSIGHT into Diversity.
Kimberly Clemenson, MS, MBA
Executive Director, Business Performance, Amgen
Kimberly has over 20 years of diverse Operations experience from various ventures into research, pharma/biotech, and entrepreneurship. She is currently Executive Director of Business Performance at Amgen and is leading an effort to accelerate potentially impactful therapies from discovery through launch to market at industry-leading speed. Kimberly joined Amgen in 2003 and has held positions of increasing responsibility in Operations Strategy, Global Operations Planning, CMC Lifecycle Management, and Global Product General Management. She spent the majority of her time as a Global Operations Leader, both leading product development teams and managing commercial products within the Operations space. Kimberly received her B.S. in Physics from Eastern Kentucky University, her M.S. in Health Physics from Texas A&M University, and an MBA from the University of California, Los Angeles. Kimberly is an avid cook and foodie and lives in the San Francisco Bay Area with her husband and two stepchildren.
Sue Desmond-Hellmann, MD, MPH
Chief Executive Officer, Bill & Melinda Gates Foundation
Sue Desmond-Hellmann, MD, MPH, is the 2018 recipient of the AWIS Pinnacle Award which recognizes her contributions in STEM as a scientist, physician, philanthropist, and mentor. As Chief Executive Officer of the Bill & Melinda Gates Foundation, Sue leads the organization’s vision for a world where every person has the opportunity to live a healthy, productive life. Under her watch, the foundation has also been pushing harder on women’s empowerment while working towards closing gender data gaps to help accelerate progress for women around the world. Forbes magazine has named her one of the world’s seven most “powerful innovators” and in her current role she champions global development by getting the right interventions, to the right populations, in the right places, to save lives. She is the recipient of numerous honors and awards. Sue was listed among Fortune magazine’s “top 50 most powerful women in business” for seven years and, in 2010, was inducted into the American Academy of Arts and Sciences and elected to the Institute of Medicine.
Jennifer Elisseeff, PhD
Professor, Johns Hopkins University
Dr. Elisseeff is the Morton Goldberg Professor and Director of the Translational Tissue Engineering Center at Johns Hopkins Department of Biomedical Engineering and the Wilmer Eye Institute with appointments in Chemical and Biological Engineering, Materials Science and Orthopedic Surgery. She was elected a Fellow of the American Institute of Medical and Biological Engineering, the National Academy of Inventors, and a Young Global Leader by World Economic Forum. In 2002 she was named by MIT Technology Review as a top innovator under 35. She is an AWIS sustaining member.
Holly J. Falk-Krzesinski, PhD
Vice President, Research Intelligence, Global Strategic Networks, Elsevier
Holly Falk-Krzesinski, PhD, is the Vice President, Research Intelligence on the Global Strategic Networks team at Elsevier, where her responsibilities center on how insights from data and analytics guide strategic planning for research institutions, funders, and science policy organizations. Dr. Falk-Krzesinski’s engagement activities include building partnerships around gender diversity and equity issues. Actively involved in promoting early career researchers and women leaders in STEM, Dr. Falk-Krzesinski co-launched the Chicago Collaboration for Women in STEM while a faculty member at Northwestern University, served as the editor-in-chief of the AWIS Magazine, is co-chair of the Gender Working Group at Elsevier, and co-authored Elsevier’s public report, “Gender in the Global Research Landscape.” Dr. Falk-Krzesinski has been an AWIS member since 1994.
Rachel Haurwitz, PhD
President and Chief Executive Officer, Caribou Biosciences, Inc.
Award Recipient, Panelist
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Bahija Jallal, PhD
President, MedImmune and Executive Vice President, AstraZeneca
As part of AstraZeneca’s Senior Executive Team, Dr. Bahija Jallal is tasked with advancing the biologic organization’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders, and pain. Dr. Jallal received a master’s degree in biology from Paris Diderot University and her doctorate in physiology from Pierre-and-Marie-Curie University. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
Leisa Johnson, PhD
Vice President, Preclinical Research & Development, 4D Molecular Therapeutics
Dr. Johnson has over 20 years of experience in cutting edge biological sciences and biotherapeutics R&D. She completed her PhD in Biology at MIT in the lab of Dr. Tyler Jacks, a world-leader in animal disease modeling. Her industry experience started as a post-doctoral associate at Onyx Pharmaceuticals, where she quickly rose to take leadership of a new oncolytic virus and gene therapy product development program. She subsequently held leadership roles at Exelixis and Genentech, where she built and directed scientific and preclinical development teams focused on supporting oncology target discovery and validation efforts as well as the development of novel small molecule drugs and therapeutic antibodies. She is currently the Vice President of Preclinical R&D at 4D Molecular Therapeutics, a leader in next-generation AAV vector discovery that is dedicated to curing patients with severe, inherited rare diseases through targeted and optimized AAV gene therapy products.
Alex Jung, MBA
Managing Director, Ernst & Young
Alex is a managing director in the Parthenon-EY practice of Ernst & Young LLP, where she works primarily on strategic transformation projects. Alex has worked with many health care and life sciences companies across the country and has developed and implemented large-scale plan design and funding strategies such as the introduction of innovative consumer-driven health care plans, health savings accounts and health improvement initiatives, including on-site pharmacies and clinics for her former clients.
Alex led corporate strategy at Walgreens, and has performed work on several large-scale transactions, mergers and acquisitions, including the divestiture of Walgreens’ pharmacy benefit manager, acquisition of AllianceBoots and other assets. She has been quoted in numerous articles in the Chicago Tribune, Business Insurance, Workforce Management magazine, Crain’s Chicago Business and other industry publications.
Sara Kenkare-Mitra, PhD
Senior Vice President, Development Sciences, Genentech
Sara Kenkare-Mitra, PhD, is senior vice president of Development Sciences at Genentech, a member of the Roche Group. Kenkare-Mitra has had a significant impact on the development of a number of medicines leading to Genentech’s key product approvals including Avastin®, Tarceva®, Lucentis®, Xolair®, Erivedge®, Perjeta®, and Kadcyla® and more than 65 Investigational New Drug applications. Sara also is an adjunct faculty at UCSF in the Department of Bioengineering and Therapeutic Sciences. She was selected one of the 150 Most Influential Business Women by San Francisco Business Times in 2011. Sara was elected to the Institute of Medicine, National Academy in 2014. She has been a member of AWIS since 2010.
Talmadge E. King, Jr., MD
Dean, School of Medicine and Vice Chancellor
Medical Affairs, University of California, San Francisco
Talmadge E. King, Jr., MD is Dean of the School of Medicine and Vice Chancellor-Medical Affairs at the University of California, San Francisco. Dr. King is a member of the National Academy Medicine, the American Academy of Arts and Sciences, the Association of American Physicians, the American Clinical and Climatological Association and the Fleischner Society. He is a Master of the American College of Physicians and a Fellow of the American College of Chest Physicians. Dr. King is a past president of the ATS and Secretary/Treasurer of the American Board of Internal Medicine. He received the Trudeau Medal from the ATS and the Breathing for Life Award from the Foundation of the ATS. His research interest is the pathogenesis, diagnosis and management of inflammatory and immunologic lung injury. His bibliography comprises more than 300 publications. He has co-authored 11 books, including the reference book Interstitial Lung Disease, now in its 5th edition.
Dana Krueger, PhD
Managing Director, Global Leader of RRA Biotech & Pharmaceuticals Practice, Russell Reynolds Associates
A PhD scientist by background, Dana Krueger leads the firm’s Global Biotech & Pharmaceuticals Practice. She focuses on leadership assignments at the executive and non-executive levels. She also advises clients across a range of sectors on senior R&D/innovation roles. Dana is based in Amsterdam.
Prior to joining Russell Reynolds Associates, Dana served as a Global Account Manager and key member of the European Life Sciences practice at the Monitor Group (now part of Deloitte). Earlier in her career, she was a Post Doctoral Fellow at Harvard University and a Fulbright Fellow at the University of Sydney.
Dana is a member of the Healthcare Business Women’s Association (HBA), and also participates in the Ivy Circle and the Harvard Club of the Netherlands.
Dana received her B.A. in Biology (summa cum laude) from Lawrence University and her A.M. and Ph.D. in Biology from Harvard University.
Ann Lee-Karlon, PhD
Senior Vice President, Portfolio Management and Operations, Genentech
Ann Lee-Karlon, PhD, is Senior Vice President at Genentech. She leads Portfolio Management and Operations with oversight for over 30 product development teams and heads business operations for the research and early development division. Prior to joining Genentech, Ann was a leader in venture development at Eli Lilly and interned at UBS investment bank in London. Ann holds an MBA from Stanford University, BS in bioengineering from UC Berkeley, and PhD in bioengineering from UC San Diego, where she was a National Science Foundation Fellow. Ann currently serves as President and Board Chair of the Genentech Access to Care Foundation. She was elected President and Board Chair of the Association of Women in Science (2014-2016), based in Washington, D.C. Ann was named a Fellow of the Aspen Institute in the inaugural Health Innovators program.
Crystal Lee, MILR
Associate Director of Human Resources, Boehringer Ingelheim
Crystal Lee is the Associate Director of Human Resources at Boehringer Ingelheim Fremont. In her current role, she advises business leaders at the biopharmaceutical manufacturing site on creating and implementing strategic human resources initiatives. Crystal is a graduate of Cornell University with a Master degree in Industrial and Labor Relations and received a Bachelors degree in Political Science from the University of Washington.
Pamela McCauley, PhD
Professor, Department of Industrial Engineering and Management Systems
University of Central Florida
Dr. Pamela McCauley leads the Human Factors in Disaster Management Research Team and serves as director of the Ergonomics Laboratory at the University of Central Florida. Dr. McCauley was recently selected to be a Jefferson Science Fellow with the U.S. State Department. Her areas of research and expertise include: ergonomics, biomechanics, fuzzy set theory, and artificial intelligence research, particularly with applications to human factors. Dr. McCauley earned her bachelor’s, master’s, and PhD in industrial engineering from the University of Oklahoma. She has been an active AWIS member since 2015.
Wendy Mayer, MBA
Vice President Strategy, Pfizer Innovative Health
Wendy Mayer, MBA, is vice president Strategy, Pfizer Innovative Health. In this role, she is responsible for articulating and evaluating strategic opportunities across Pfizer’s Innovative portfolio (Vaccines, Oncology, Internal Medicine, Rare Disease, Immunology & Inflammation, and Consumer Health), including business development and transformative innovation. She joined Pfizer in 1997, and has had various roles across different aspects of the commercial organization. She is an AWIS sustaining member.
Evening News Anchor, KRON 4
Master of Ceremonies
Pam Moore joined KRON 4 in March 1991 as an anchor and general assignment reporter and anchors the evening newscasts. Pam’s work on KRON 4’s five-part news series “About Race” garnered a number of awards, including a prestigious George Foster Peabody Award, the Pew Center Batten Prize for Civic Journalism, an In-Depth Reporting Award from the Northern California Chapter of the Society of Professional Journalists, top honors from the Black Filmmakers Hall of Fame and Best Documentary Award from the California Associated Press Television Radio Association. In addition, Pam was nominated for an Emmy for the special “Selma to Ferguson”. She has been inducted into the National Academy of Television Arts & Sciences Silver Circle, honoring her significant contribution to Northern California television and honored for her career achievements by the Society of Professional Journalism, NorCal. Pam is a member of the Bay Area Black Journalists Association, has worked in the past with the Black Journalists Association of Southern California, and was a former vice president for broadcast for the National Association of Black Journalists.
Tony Prophet, MBA
Chief Equality Officer, Salesforce, Inc.
Tony Prophet leads Salesforce’s Equality initiatives, focusing on gender, LGBTQ, and racial issues—ensuring the company reflects the diversity and upholds the values of the communities it serves. He reports directly to the CEO and Chairman Marc Benioff. Prophet is also a board member of Gannett where he chairs the Transformation Committee. He also serves on the board of College Track.
Previously, Prophet was the corporate vice president of Windows and Search Marketing at Microsoft—responsible for the business planning and product marketing of the Windows, Bing, MSN and Cortana brands. Before that, he led the worldwide operations of what is now HP Inc. with direct responsibility exceeding $50B. Prior to that, he led the worldwide operations of Carrier Corporation. He began his career in consulting and rose from associate to partner with Booz Allen, co-founding the firm’s Los Angeles office.
Throughout his career, Prophet has worked for social justice including addressing the root causes of migratory worker flows, educating female workers in developing countries on reproductive health issues and reducing supply chain greenhouse gas footprint.
Prophet holds a BSIE degree from General Motors Institute and an MBA from the Stanford Graduate School of Business attending as a GM Fellow.
Sara Radcliffe, MPH
President and Chief Executive Officer, California Life Sciences Association
Sara Radcliffe was appointed the president and chief executive officer of the California Life Sciences Association (CLSA) in December 2014. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College.
Karene Richards, MA
CEO, The Karene Group LLC
Karene Richards is a capital markets quantitative expert and women’s advocate with over 14 years’ experience in the investment banking industry. Ms. Richards most notably built the first carbon finance model for the World Bank in addition to a mortgage backed security model that generated $25M for Route 66 Ventures. She received a master of financial mathematics and statistics from Columbia University and an undergraduate degree in electrical engineering from Howard University. She a member of Women in Housing and Finance and has been an AWIS benefactor since 2016.
Melinda Richter, MBA
Global Head, Johnson & Johnson Innovation, JLABS
Melinda Richter, MBA, is the Global Head of Johnson & Johnson Innovation, JLABS. In her role, she fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. Melinda has received numerous industry awards including: the PharmaVOICE 100; Fierce Biotech Top 15 Women; Most Influential Women in Business (San Francisco Business Times); MM&M 2017 Healthcare Transformer; BIO Super Hero; and Fast Company’s Most Innovative Company in Biotech. She serves on various boards and advisory panels and is currently board member and Treasurer of the California Life Sciences Association (CLSA).
Senior Associate, Unshackled Ventures
Maria Salamanca, Senior Associate, has worked with Unshackled Ventures, an early stage fund focused on immigrant founders, since the firm launched in 2015. A Colombian immigrant herself, she has worked to scale out the firm’s deal sourcing as well as sourced her own deals. She also organizes Startup Weekend: Latinx Tech Edition and her newsletter, Making a Technie. Maria has been recognized by Forbes as a 30 Under 30: Venture Capital and a Fellow at Higher Ground Labs. Maria received a BA in Government and Legal Studies at the University of California, Berkeley and attended the Summer Venture in Management Program at Harvard University.
Marc Tessier-Lavigne, MD, FRS FRSC FMedSci
President and Bing Presidential Professor, Stanford University
Pioneering neuroscientist Marc Tessier-Lavigne became Stanford University’s 11th president on September 1, 2016. He returned to Stanford after serving as president of The Rockefeller University, a graduate biomedical research university in New York city. From 2001 to 2005, he was a professor of biological sciences at Stanford, where he held the Susan B. Ford Professorship in the Humanities and Sciences. He has also held faculty positions at the University of California, San Francisco, and executive positions at biotechnology company Genentech.
Sue Windham-Bannister, PhD
Managing Director, Biomedical Innovation Advisors, LLC and President and CEO, Biomedical Growth Strategies, LLC
Dr. Susan Windham-Bannister is a world-renowned innovation expert, recognized by the Boston Globe as one of the “10 Most Influential Women in Biotech” in 2013. Windham-Bannister currently serves as managing partner of Biomedical Innovation Advisors LLC, as well as the president and CEO of Biomedical Growth Strategies, LLC. She received a BA from Wellesley College, a doctorate in health policy and management from the Florence Heller School at Brandeis University, and a doctor of science from Worcester Polytechnic Institute (honoris causa). She has been an AWIS member since 2016.
Wendy B. Young, PhD
Senior Vice President, Small Molecule Drug Discovery, Genentech
Wendy B. Young, PhD is Senior Vice President of Small Molecule Drug Discovery at Genentech in San Francisco, CA. In this role she leads an internal team of more than 350 scientists that discover, invent and develop new medicines for patients. Wendy is a chemist by training and has extensive experience leading drug discovery teams. She led the team and is an inventor of fenebrutinib, a bruton tyrosine kinase (Btk) inhibitor, which is in clinical trials for RA, lupus and urticaria. Wendy received a B.A./M.S. degree in chemistry at Wake Forest University, a Ph.D. from Princeton University, and was an American Cancer Society postdoctoral fellow at Memorial Sloan Kettering Cancer Center. Prior to Genentech, Wendy led discovery efforts at Axys/Celera. In 2015, Wendy was recognized by the San Francisco Business Times as one of San Francisco Bay Area’s “Most Influential Business Women.” In 2017, Wendy was elected Chair of the National ACS Medicinal Chemistry Division and now serves as the Past Chair.
© 2017 Association for Women in Science. All Rights Reserved.